PHYSIOLOGICAL PHARMACOKINETIC MODEL FOR CEFTAZIDIME DISPOSITION IN THE RAT AND ITS APPLICATION TO PREDICTION OF PLASMA-CONCENTRATIONS IN HUMANS

被引:16
作者
GRANERO, L [1 ]
CHESAJIMENEZ, J [1 ]
MONSERRAT, V [1 ]
ALMELA, M [1 ]
GIMENO, MJ [1 ]
TORRESMOLINA, F [1 ]
PERISRIBERA, JE [1 ]
机构
[1] UNIV VALENCIA, FAC PHARM, DEPT PHARM & PHARMACEUT TECHNOL, DIV BIOPHARMACEUT & PHARMACOKINET, E-46100 BURJASSOT, SPAIN
关键词
CEFTAZIDIME; PHYSIOLOGICAL PHARMACOKINETIC MODEL; INTERSPECIES PHARMACOKINETIC EXTRAPOLATION; RATS;
D O I
10.1016/0928-0987(93)90012-Y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A physiological pharmacokinetic model for the disposition of ceftazidime in the rat was developed. The model is composed of 10 compartments which represent most of the organs and tissues of the body. Ceftazidime concentration-time profiles in the organs and tissues represented in the model were simulated and compared with the observed concentration-time data after i.v. administration of 5 and 20 mg of antibiotic. The model gave an acceptable description of the observed data. The steady-state volume of distribution and total clearance of ceftazidime in healthy humans predicted from data obtained in the rat (0.211/kg and 113 ml/min, respectively) were similar to the values reported for these parameters by several authors. The model was scaled to humans by using the tissue volumes and plasma flow rates corresponding to a standard man, the tissue-to-plasma partition coefficients determined in rats, and the total plasma clearance of ceftazidime observed in humans. Good predictions of plasma concentrations of ceftazidime in normal subjects and patients with various degrees of impaired renal function were obtained.
引用
收藏
页码:3 / 11
页数:9
相关论文
共 23 条
[1]   QUANTITATIVE RELATIONS IN THE PHYSIOLOGICAL CONSTITUTIONS OF MAMMALS [J].
ADOLPH, EF .
SCIENCE, 1949, 109 (2841) :579-585
[2]  
BENOWITZ N, 1974, CLIN PHARMACOL THER, V16, P87
[3]   METHOTREXATE PHARMACOKINETICS [J].
BISCHOFF, KB ;
DEDRICK, RL ;
ZAHARKO, DS ;
LONGSTRETH, JA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (08) :1128-+
[4]  
BOXENBAUM H, 1988, INTERET LIMITES PHAR, P1
[5]   COMPARISON OF THE PHARMACOKINETICS OF CEFTAZIDIME AND MOXALACTAM AND THEIR MICROBIOLOGICAL CORRELATES IN VOLUNTEERS [J].
DRUSANO, GL ;
STANDIFORD, HC ;
FITZPATRICK, B ;
LESLIE, J ;
TANGTATSAWASDI, P ;
RYAN, P ;
TATEM, B ;
MOODY, MR ;
SCHIMPFF, SC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (03) :388-393
[6]  
GABRIELSSON JE, 1982, J PHARMACOKINET BIOP, V16, P183
[7]  
Gibaldi M., 1982, PHARMACOKINETICS, Vsecond
[8]  
Guyton A. C., 1981, TXB MED PHYSL
[9]   THE COMPARATIVE PHARMACOKINETICS OF CEFTAZIDIME AND CEFOTAXIME IN HEALTHY-VOLUNTEERS [J].
HARDING, SM ;
MONRO, AJ ;
THORNTON, JE ;
AYRTON, J ;
HOGG, MIJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1981, 8 :263-272
[10]   COMPARATIVE PHYSIOLOGICALLY BASED PHARMACOKINETICS OF HEXOBARBITAL, PHENOBARBITAL, AND THIOPENTAL IN THE RAT [J].
IGARI, Y ;
SUGIYAMA, Y ;
AWAZU, S ;
HANANO, M .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (01) :53-75